Phibro Animal Health appoints Daniel Bendheim as CEO effective July 1, 2026, with performance-based RSU grant

PHIBRO ANIMAL HEALTH CORP

Daniel Bendheim appointed CEO & President effective July 1, 2026; base salary $850k, target bonus 50% of salary.
Granted 300,000 performance-based RSUs vesting based on 90-day average stock price from $70 to $100+ by June 30, 2031.
Severance: 18 months COBRA if terminated without cause; 6 months base salary for death/disability.
Employment agreement includes confidentiality, non-compete, non-solicitation, non-disparagement covenants.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Daniel Bendheim

Chief Executive Officer and President

PAHC · PHIBRO ANIMAL HEALTH CORP

Effective: 2026-07-01
Filed: June 26, 2026, 5:07 PM ET

On June 25, 2026, in connection with Daniel (Dani) Bendheim’s appointment to the role of Chief Executive Officer and President of the Company effective July 1, 2026

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Daniel Bendheim was appointed as Chief Executive Officer and President at PHIBRO ANIMAL HEALTH CORP.

Action: appointed
Role: Chief Executive Officer and President

Exact text from the filing

On June 25, 2026, in connection with Daniel (Dani) Bendheim’s appointment to the role of Chief Executive Officer and President of the Company effective July 1, 2026

View on SEC.gov

PHIBRO ANIMAL HEALTH CORP filing history →

Source: SEC EDGAR

accession 0001104659-26-078323

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.